Çelebi G, Ayyildiz A, Çiftci Inceoğlu S, Kuran B
Bahçeşehir University, Göztepe Medical Park Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey.
Ministry of Health, Çam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey.
Rehabilitacion (Madr). 2025 Jan-Mar;59(1):100876. doi: 10.1016/j.rh.2024.100876. Epub 2025 Jan 7.
Spasticity developing in the upper extremity in stroke patients causes disability by limiting movement and causing pain. This study investigates the effects of botulinum toxin injections on pain, functionality, spasticity, and range of motion in hemiplegic patients with post-stroke spasticity.
The study involved a double-blind, prospective, randomized controlled trial with thirty-one stroke patients aged 35-80 who developed upper extremity spasticity. The study group (n=16) received botulinum toxin-A (BT-A) injections in addition to conventional rehabilitation and stretching exercises, while the control group (n=15) received placebo injections. Evaluations were conducted before treatment, in the second week, and three months after treatment. The study evaluated pain relief through the Visual Analog Scale (VAS), assessed spasticity with the Modified Ashworth Scale (MAS), and measured functionality using the Fugl Meyer Assessment Scale (FMAS) and the Box Block Test (BBT).
The mean age of patients was 56.03±11.81. The median time after stroke was 24 months. The BT-A group demonstrated significantly lower VAS and MAS scores compared to controls at both 2 weeks and 3 months after treatment. Additionally, the BT-A group showed significantly higher changes in arm, wrist, and total FMAS scores compared to the control group. However, no significant difference was found in terms of hand, coordination, and speed FMAS score changes.
The results of our study demonstrated that BT-A injection with ultrasonography guidance is an effective method for alleviating pain caused by passive shoulder movement, significantly reducing spasticity, and markedly improving motor functions.
中风患者上肢出现的痉挛会限制运动并引起疼痛,从而导致残疾。本研究调查肉毒杆菌毒素注射对中风后痉挛性偏瘫患者的疼痛、功能、痉挛和运动范围的影响。
本研究为双盲、前瞻性、随机对照试验,纳入31例年龄在35 - 80岁且出现上肢痉挛的中风患者。研究组(n = 16)除接受常规康复和伸展运动外,还接受肉毒杆菌毒素A(BT - A)注射,而对照组(n = 15)接受安慰剂注射。在治疗前、治疗后第二周和治疗后三个月进行评估。通过视觉模拟量表(VAS)评估疼痛缓解情况,使用改良Ashworth量表(MAS)评估痉挛程度,并使用Fugl Meyer评估量表(FMAS)和箱块测试(BBT)测量功能。
患者的平均年龄为56.03±11.81。中风后的中位时间为24个月。治疗后2周和3个月时,BT - A组的VAS和MAS评分均显著低于对照组。此外,与对照组相比,BT - A组在手臂、手腕和总FMAS评分方面的变化显著更高。然而,在手部、协调性和速度FMAS评分变化方面未发现显著差异。
我们的研究结果表明,超声引导下的BT - A注射是缓解被动肩部运动引起的疼痛、显著降低痉挛程度并明显改善运动功能的有效方法。